Phase 3 Clinical Trials With Primary Completion Dates in July 2024

This is a list of Phase 3 trials with primary completion dates in July 2024 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
EQ Equillium, Inc. 2024-07-01 Phase 3 NCT05263999 A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)
IONS Ionis Pharmaceuticals, Inc. 2024-07-01 Phase 3 NCT05071300 A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
NBTX Nanobiotix S.A. 2024-07-01 Phase 3 NCT04892173 NBTXR3 With or Without Cetuximab in LA-HNSCC
OCS Oculis Holding AG 2024-07-01 Phase 3 NCT06128369 Study Evaluating the Efficacy and Safety of OCS-01 Eye Drops in Subjects Following Cataract Surgery
PYPD PolyPid Ltd. 2024-07-01 Phase 3 NCT04411199 D-PLEX 312 - Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional Infection (SHIELD II)
SLRN Acelyrin, Inc. 2024-07-01 Phase 3 NCT05905783 Hidradenitis Suppurativa Study of Izokibep
VRDN Viridian Therapeutics, Inc. 2024-07-01 Phase 3 NCT05176639 A Safety, Tolerability and Efficacy Study of VRDN 001 in Healthy Volunteers and Persons With Thyroid Eye Disease (TED)